Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06700841 Immediate release tablets
PF-06700841 Immediate release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06700841: IR followed by MR | EXPERIMENTAL | Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR) |
| PF-06700841: MR followed by IR | EXPERIMENTAL | Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR) |
| Name | Type | Description |
|---|---|---|
| PF-06700841 Immediate release tablets | DRUG | Small molecule tablets in immediate release form |
| PF-06700841 Modified release tablets | DRUG | Small molecule tablets in modified release form |
Key Inclusion Criteria: * Healthy male, and female participants between the ages of 18 and 55 years at the time of screening, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse...
PF-06700841 Immediate release is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It is formulated as immediate release tablets. The drug has been studied in a Phase 1 clinical trial in healthy participants. Its therapeutic area is classified as other, and specific indications have not been disclosed.
PF-06700841 Immediate release is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical program for this investigational small molecule.
PF-06700841 Immediate release is in Phase 1 clinical development. The single trial conducted for this formulation was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
PF-06700841 Immediate release has been evaluated in one completed Phase 1 trial, NCT03765554, titled "Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations." The trial enrolled 8 healthy participants in Belgium and was randomized and controlled, though not double-blind.
Yes, PF-06700841 Immediate release tablets is another name for PF-06700841 Immediate release. Both refer to the same investigational small molecule developed by Pfizer, Inc. (PFE) that has been studied in a Phase 1 clinical trial.